Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 6/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491512 | 0.93 | MCL1 (0.41) | DCTPP1PABPC1TDP1PDE3BPDE3A | |
| SCHEMBL6497299 | 0.93 | PDE3B (0.40) | DCTPP1PDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL6502699 | 0.92 | MCL1 (0.46) | DYRK1ADCTPP1MAPTLMNATP53 | |
| SCHEMBL6500616 | 0.91 | MCL1 (0.38) | DYRK1ADCTPP1PDE3BPDE3AP2RY12 | |
| SCHEMBL6488241 | 0.86 | MCL1 (0.43) | DCTPP1PDE3BPDE3AP2RY12MAPT | |
| SCHEMBL6487942 | 0.85 | MCL1 (0.42) | DCTPP1PDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6497204 | 0.85 | DCTPP1 (0.44) | DCTPP1PDE3BPDE3AP2RY12MAPT | |
| SCHEMBL6501386 | 0.84 | MCL1 (0.48) | DCTPP1PDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6502915 | 0.84 | SMN1; SMN2 (0.44) | PABPC1TDP1PDE3BPDE3AP2RY12 | |
| SCHEMBL6488344 | 0.83 | MCL1 (0.47) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | DYRK1A 4466/4885DCTPP1 1534/4885PABPC1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.